Weiting Zhang1, Teri N. Kreisl1, Jeffrey Solomon2, Richard C. Reynolds1, Daniel R. Glen1, Robert W. Cox1, Howard A. Fine1, John A. Butman1
1National Institutes of Health,
DCE-MRI was used to monitor the effects of bevacizumab on physiologic measures of tumor vascularity, such as blood brain barrier permeability, represented as Ktrans , and vascular perfusion represented as fpv, in patiens with recurrent anaplastic astrocytoma. Bevacizumab dramatically reduces Ktrans, fpv, and enhancing tumor volume as early as 4 days and this effect persisted at least for 4 weeks. Tumors with larger baseline enhancing tumor volume and greater baseline Ktrans were related to poorer prognosis.